The longevity industry has reached an inflection point. With companies like Function Health raising hundreds of millions in venture capital, biological age testing has moved from academic curiosity to investable market category. Yet behind the funding headlines lies a more nuanced reality: a field grappling with fundamental questions about accuracy, stability, and clinical utility.
